Jeffrey Van Ness

USPTO Granted Patents = 35 (Patent Applications = 1)

CIPO Patents = 2

EPO Patents = 4 (Patent Applications = 1)

Average Co-Inventor Count = 3.4

ph-index = 21

Forward Citations = 2,470(Granted Patents)

Location History:

Bothell, WA (US) (1992 - 1997)
Claremont, CA (US) (2005 - 2010)
Seattle, WA (US) (1999 - 2017)

Company Filing History:

9 out of 9

Qiagen Genomics, Inc.

patents

7 out of 90

Darwin Discovery Limited

Operon Biotechnologies, Inc.

patents

5. 2 out of 5,175

Becton Dickinson and Company Limited

Keck Graduate Institute

where one patent can have more than one assignee

Years Active: 1992-2017

Loading Chart...

35 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 9791462 - Compositions and methods for increasing bone mineralization (2017-10-17),

2. 8986685 - Compositions and methods for increasing bone mineralization (2015-03-24),

3. 7994299 - Compositions and methods for increasing bone mineralization (2011-08-09),

4. 7977312 - Compositions and methods for increasing bone mineralization (2011-07-12),

5. 7758858 - Antibodies associated with alterations in bone density (2010-07-20),

6. 7642344 - Methods and compositions for determining the sequence of nucleic acid molecules (2010-01-05),

7. 7572899 - Compositions and methods for increasing bone mineralization (2009-08-11),

8. 7247434 - Methods and compositions for determining the sequence of nucleic acid molecules (2007-07-24),

9. 7192583 - Methods for modulating bone mineralization (2007-03-20),

10. 7112423 - Nucleic acid amplification using nicking agents (2006-09-26),

11. 7052846 - Methods and compositions for analyzing nucleic acid molecules utilizing sizing techniques (2006-05-30),

12. 6884586 - Methylation analysis using nicking agents (2005-04-26),

13. 6815212 - Methods and compositions for enhancing sensitivity in the analysis of biological-based assays (2004-11-09),

14. 6803453 - Antibodies associated with alterations in bone density (2004-10-12),

15. 6623928 - Methods and compositions for determining the sequence of nucleic acid molecules (2003-09-23),

Title: Innovations and Contributions of Jeffrey Van Ness in Bone Mineralization

Introduction

Jeffrey Van Ness, based in Claremont, CA, is a prominent innovator with a remarkable portfolio of 35 patents. His research primarily focuses on innovative solutions in the field of bone mineralization, contributing significantly to the medical and biopharmaceutical sectors.

Latest Patents

Among his latest patents, Jeffrey has developed compositions and methods for increasing bone mineralization. He has introduced a novel class or family of TGF-β binding proteins, which are essential for enhancing bone mineral density. This patent also includes innovative assays designed for selecting molecules that promote bone mineralization. Additionally, he has patented pharmaceutical compositions that comprise anti-sclerostin antibodies along with inhibitors of bone resorption, showcasing his commitment to advancing bone health therapies.

Career Highlights

Throughout his career, Jeffrey Van Ness has demonstrated a consistent commitment to research and development. He has played a pivotal role in enhancing scientific understanding and treatment strategies related to bone health. His work in various companies, including Qiagen Genomics, Inc. and Darwin Discovery Limited, reflects his dedication to bridging the gap between laboratory research and practical applications in medicine.

Collaborations

Jeffrey has collaborated with notable professionals such as John Thomas Mulligan and John C Tabone, further enriching his experience and expanding the scope of his innovative contributions. These partnerships have resulted in meaningful advancements in the development of therapeutic solutions for bone conditions.

Conclusion

In conclusion, Jeffrey Van Ness's contributions to the field of bone mineralization stand as a testament to his inventive spirit and dedication to scientific research. With his extensive patent portfolio and collaborative efforts, he continues to pave the way for future innovations in the biopharmaceutical industry, impacting the lives of many seeking improved bone health solutions.

This text is generated by artificial intelligence and may not be accurate.